Physician profile
John Blake Epling
NPI 1811332166
$27,768.29
in general payments reported to CMS, 2019-2025
46 companies · $6,504 in 2025
The $6,504 reported for 2025 was more than what 88% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,752 · 2020: $1,787 · 2021: $2,986 · 2022: $2,840 · 2023: $1,261 · 2024: $2,638 · 2025: $6,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,896 · Food and Beverage: $3,706 · Travel and Lodging: $1,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,896.00 |
| Food and Beverage | $3,706.33 |
| Travel and Lodging | $1,800.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $9,814.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $6,995.59 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Medtronic, INC. | $1,621.21 | 2023-2025 | Minimed 780g, Minimed 770g |
| Astrazeneca Pharmaceuticals LP | $1,090.87 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $1,046.91 | 2019-2023 | Mounjaro, Jardiance |
| Amgen INC. | $1,014.12 | 2019-2025 | Evenity, Tepezza, Prolia |
| Sanofi-Aventis U.S. LLC | $922.36 | 2019-2023 | |
| Tandem Diabetes Care, INC. | $857.50 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $850.19 | 2020-2025 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.68 | 2019-2025 | Jardiance, Tradjenta |
| Abbvie INC. | $404.63 | 2019-2025 | |
| Insulet Corporation | $400.34 | 2019-2024 | Omnipod |
| Phathom Pharmaceuticals, INC. | $230.25 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $220.09 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $195.86 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Epling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.